NEXT Financial Group Inc trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 35.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,677 shares of the medical research company’s stock after selling 2,568 shares during the quarter. NEXT Financial Group Inc’s holdings in Thermo Fisher Scientific were worth $888,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in TMO. Bank of Nova Scotia Trust Co. acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $106,000. Ropes Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 97 shares during the period. Atlantic Trust LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $138,000. Acrospire Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 66.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock worth $174,000 after buying an additional 400 shares during the period. Finally, Glassman Wealth Services grew its position in shares of Thermo Fisher Scientific by 23.1% during the 2nd quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock worth $181,000 after buying an additional 195 shares during the period. Hedge funds and other institutional investors own 86.25% of the company’s stock.
TMO has been the subject of several analyst reports. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Leerink Swann boosted their target price on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research report on Monday, October 9th. Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. Finally, BTIG Research initiated coverage on Thermo Fisher Scientific in a research report on Friday, January 5th. They set a “buy” rating and a $230.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $212.21.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter in the previous year, the business posted $2.03 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% on a year-over-year basis. analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the sale, the chief executive officer now owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.49% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2018/01/17/next-financial-group-inc-lowers-position-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.